TB Clip 2021년 11월호 본문 이미지

편집자 한마디!

국내외 결핵(TB) 뉴스

학술연구자료

STOP-TB 코리아 소식

코로나19 팬데믹으로 항감염제 및 백신의 중요성이 부각되면서 공공 및 민간의 투자가 역사 상 최고치를 기록하고 있습니다. 이에 글로벌 제약·바이오사들은 경쟁사를 포함해 데이터 공유 및 협업을 확대했고, 규제기관 역시 유연한 대응을 통해 빠른 시간에 코로나19 백신이 개발될 수 있었습니다. 이와 반대로 결핵진단, 치료 예방에 대한 전 세계 지출은 58억달러에서 2020년 53억달러로 감소 했으며, 2022년까지 결핵대응 연간예산을 130억달러로 높이자는 목표의 절반에도 미치지 못하는 실적입니다. 다행히도 Global fund 에서는 120억 달러를 넘어서는 모금액에 대해서는 결핵할당 금액의 비율을 18%에서 25%로 늘려 대응한다고 하니, 코로나와 비교하기는 힘들겠으나 좀 더 많은 투자가 진행되기를 기대해 봅니다.

In order to increase the knowledge base for normative guidance on optimal treatment modalities for drug-resistant tuberculosis (DR-TB), WHO is announcing a publicly accessible global individual patient data (IPD) platform for drug-resistant tuberculosis treatment (DR-TB-IPD). This will be a secure but accessible platform containing outcomes of over 10,000 drug-resistant TB patients as the starting point and expanding this with data received in response to a recent public call for data.

There has been substantial increase of tools to generate, analyse and use data and evidence to support discussion and decision-making by National TB Programs (NTPs) and their partners. In this context, the World Health Organization released a new Compendium of data and evidence-related tools for use in TB planning and programming, expected to help NTPs and their national stakeholders to understand how and when these different tools could be used.

On 29 October 2021, the TB Europe Coalition in collaboration with the PAS Center and the World Health Organization Regional Office for Europe hosted a high-level online event to present a new publication 'Standardized package of community-based support services to improve TB outcomes - a guide for affected community and civil society organizations and National TB Programs and policy makers in Eastern Europe and Central Asia'. The guide is available in English and Russian and can be accessed here. Recording of the event is available here.

Five developments in the screening, diagnosis, and treatment of TB in children presented at the 52nd Union World Conference on Lung Health, including recognition of the role Delamanid and Bedaquiline can play.

The TB Europe coalition has released a standardised package of community-based support services to improve TB care.

TB survivors from all the G20 countries said it was time to reverse decades of underinvestment in the “disease of injustice”. The TB Vaccine Advocacy Roadmap group, a new coalition of organisations, said G20 finance leaders need to increase funding almost tenfold, as it has never exceeded more than $120m in a year.

Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness - News & Stories - The Global Fund to Fight AIDS, Tuberculosis and Malaria

The University of Auckland, London School of Hygiene and Tropical Medicine, and the University College London, are conducting a short 10-minute survey on behalf of the World Health Organization (WHO), on user preferences of TB skin testing to inform the upcoming WHO TB testing guidelines. All people who wish to contribute are invited to complete the survey - you do not have to have experience of a skin test yourself. Of particular interest are the views of people with TB, health providers and others involved in TB care such as lab technicians and TB program managers. To access the survey, click here.

The 6th Global Forum on TB Vaccines will be held on 22-24 February 2022 as a hybrid event, with options for in-person and virtual participation. Participant support is available for students, post-docs, early career researchers, advocates, affected communities, and participants from lower- and middle-income countries. Applications for participant support are now being accepted. Applications for travel support are due on 30 November 2021; applications for registration and technical support are due by 15 January 2022. For detailed information, click here.

The screening, diagnosis, and treatment of TB in children remain far from optimal – and in many respects lag behind what can be done for adults. Spotlight summarized five developments in paediatric TB presented at the 52nd Union World Conference on Lung Health, held virtually on 19-22 October 2021.

The Global Health Innovative Technology (GHIT) Fund announced a total of approximately 750 million yen (US$6.6 million) to invest in six partnerships to develop new lifesaving drugs for malaria and Chagas disease, a vaccine for malaria, and diagnostics for TB. To read the full announcement, click here.

The Global Fund to Fight AIDS, Tuberculosis and Malaria released the first TB Quarterly Update. It will be produced on a quarterly basis to share information on the achievements, tools, guidance, best practices and highlights of the TB Strategic Initiative and other TB-related activities.

The UK Health Security Agency released the latest annual report for TB in England. It shows reported cases of TB fell in England in 2020, reducing rates from 8.4 per 100,000 in 2019 to 7.3 per 100,000. However, the decline in cases must be interpreted with caution, as the COVID-19 pandemic saw a reduction in social mixing and impacted on both access to healthcare and migration patterns in England.

Vietnam is the first country in the world to routinely use an innovative method to diagnose TB using stool. The Simple One-Step (SOS) Stool Method, developed by KNCV Tuberculosis Foundation, is implemented in 10 healthcare facilities across the country. This simple and painless test is an important development for diagnosing TB in children under the age of five and people living with HIV.

The Lancet publishes an assessment of the epidemiology, genetic basis, and treatment outcomes associated with bedaquiline resistance, using data from South Africa.

A comment piece in The Lancet on the potential perils of a drug protection framework for TB.

The use of nucleic acid amplification testing for TB increased in the United States (US) between 2011 and 2017, although nearly half of US TB cases did not include one of the tests, according to a study published in Open Forum Infectious Diseases.

Data revealed that cytomegalovirus was independently associated with latent TB infection, and both were associated with high levels of C-reactive protein, suggesting enhanced systemic inflammation, researchers reported in Open Forum Infectious Diseases.

The TB vaccine in use today is essentially the same as the Bacillus Calmette–Guérin (BCG) vaccine introduced in July 1921. The COVID-19 pandemic has shown that it’s possible to produce new vaccines in one year, not 100 — provided that there is funding and political will. Source: Nature

In patients with TB, a host 22-gene RNA-based model has been identified that may be predictive of individual treatment durations with antimicrobial therapy, potentially leading to a substantially shorter treatment durations for many patients. This was among the results of an analysis recently published in the European Respiratory Journal.

Approximately one-third of patients with TB-destroyed lung experienced postoperative complications, with certain subgroups at higher risk, according to new data published in BMC Pulmonary Medicine.